{"id":295,"date":"2024-08-01T21:15:04","date_gmt":"2024-08-01T21:15:04","guid":{"rendered":"https:\/\/www.libertymanagement.us\/fda-support\/?p=295"},"modified":"2024-08-01T21:15:04","modified_gmt":"2024-08-01T21:15:04","slug":"drug-master-files","status":"publish","type":"post","link":"https:\/\/www.libertymanagement.us\/fda-support\/2024\/08\/01\/drug-master-files\/","title":{"rendered":"Drug Master Files"},"content":{"rendered":"\n<p class=\"wp-block-paragraph\">A <a href=\"https:\/\/www.fdahelp.us\/drug-master-files.html\">Drug\nMaster File (DMF)<\/a> is a confidential and detailed document submitted to the US\nFDA by a drug manufacturer. It contains comprehensive information about\nfacilities, processes, or articles used in the manufacturing, processing,\npackaging, and storing of human drug products. DMF submission is not required\nby FDA regulation. DMF is solely submitted at the discretion of the DMF holder.\nA MDF is not approved or disapproved. Technical contents of a DMF may be\nreviewed only in connection with the review of an IND, NDA, ANDA, or an Export\nApplication. DMF allows FDA to review this information to ensure the quality\nand safety of the drug products without disclosing proprietary information to\nthe drug product&#8217;s sponsor.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">The submission of a DMF can be made by:<\/p>\n\n\n\n<ol class=\"wp-block-list\"><li><a href=\"https:\/\/www.fdahelp.us\/api-listing.html\">API<\/a> manufacturers<\/li><li>Excipient\n     manufacturers: <\/li><li>Container\n     Closure System manufacturers<\/li><li><a href=\"https:\/\/www.fdahelp.us\/drugs.html\">Drug Product<\/a> manufacturers<\/li><\/ol>\n\n\n\n<p class=\"wp-block-paragraph\">Types of DMF:<\/p>\n\n\n\n<ol class=\"wp-block-list\"><li>Type\n     I: Manufacturing Site, Facilities, Operating Procedures, and Personnel\n     (discontinued since September 2010).<\/li><li>Type\n     II: Drug Substance, Drug Substance Intermediate, and Material Used in\n     Their Preparation, or Drug Product.<\/li><li>Type\n     III: Packaging Material.<\/li><li>Type\n     IV: Excipient, Colorant, Flavor, Essence, or Material Used in Their\n     Preparation.<\/li><li>Type\n     V: FDA Accepted Reference Information <\/li><\/ol>\n\n\n\n<p class=\"wp-block-paragraph\">Non-US DMF applicants are required to appoint a <a href=\"https:\/\/www.fdahelp.us\/fda_registration\/us-fda-agents-requirements.html\">US\nAgent<\/a> in their DMF for FDA communication purpose.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\"><a href=\"https:\/\/www.fdahelp.us\/\">Liberty Management Group\nLtd.<\/a> can help you DMF submissions &amp; US Agent service.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\"><em>Namrata <\/em><\/p>\n\n\n\n<p class=\"wp-block-paragraph\"><em>Regulatory Consultant<\/em><\/p>\n\n\n\n<p class=\"wp-block-paragraph\"><a href=\"mailto:support@libertymanagement.us\"><em>support@libertymanagement.us<\/em><\/a><\/p>\n\n\n\n<p class=\"wp-block-paragraph\"><a href=\"http:\/\/www.fdahelp.us\">http:\/\/www.fdahelp.us<\/a><\/p>\n\n\n\n<p class=\"wp-block-paragraph\"><\/p>\n","protected":false},"excerpt":{"rendered":"<p>A Drug Master File (DMF) is a confidential and detailed document submitted to the US FDA by a drug manufacturer. It contains comprehensive information about facilities, processes, or articles used in the manufacturing, processing, packaging, and storing of human drug products. DMF submission is not required by FDA regulation. DMF is solely submitted at the &hellip; <a href=\"https:\/\/www.libertymanagement.us\/fda-support\/2024\/08\/01\/drug-master-files\/\" class=\"more-link\">Continue reading<span class=\"screen-reader-text\"> &#8220;Drug Master Files&#8221;<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[72,73,37],"class_list":["post-295","post","type-post","status-publish","format-standard","hentry","tag-dmf","tag-drug-master-file","tag-us-agent"],"_links":{"self":[{"href":"https:\/\/www.libertymanagement.us\/fda-support\/wp-json\/wp\/v2\/posts\/295","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.libertymanagement.us\/fda-support\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.libertymanagement.us\/fda-support\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.libertymanagement.us\/fda-support\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.libertymanagement.us\/fda-support\/wp-json\/wp\/v2\/comments?post=295"}],"version-history":[{"count":1,"href":"https:\/\/www.libertymanagement.us\/fda-support\/wp-json\/wp\/v2\/posts\/295\/revisions"}],"predecessor-version":[{"id":296,"href":"https:\/\/www.libertymanagement.us\/fda-support\/wp-json\/wp\/v2\/posts\/295\/revisions\/296"}],"wp:attachment":[{"href":"https:\/\/www.libertymanagement.us\/fda-support\/wp-json\/wp\/v2\/media?parent=295"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.libertymanagement.us\/fda-support\/wp-json\/wp\/v2\/categories?post=295"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.libertymanagement.us\/fda-support\/wp-json\/wp\/v2\/tags?post=295"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}